Michelle Rubin

Michelle Rubin

First Annual STAND AND DELIVER™ Winner – 2012

Director, Autism After 21

Boca Raton, Florida
www.autismafter21.org

"Autism After 21 is working to solve the next piece of the puzzle, a productive independent life for adults with autism." – Michelle Rubin

Michelle Rubin didn't plan on being an advocate for those with special needs, but when her son Scott was diagnosed with autism at the age of 2 she quickly became one. Michelle's quiet determination and inspiration comes from her son Scott, as well as the many others she has fought for over the past two decades.

Michelle is the creator and founder of Autism After 21, an organization with a mission to provide opportunities and services for autistic adults over the age of 21. As last year's winner of the STAND AND DELIVER™ contest, Michelle knows first-hand the sacrifice and dedication it takes to make a real difference in her community, and she is excited to help with the next generation of inspiring nominations for STAND AND DELIVER™.

Merz Aesthetics, Inc., exclusive distributor of Asclera^® (polidocanol) Injection, congratulates Michelle Rubin, Director, Autism After 21, on winning the Asclera^® STAND AND DELIVER™ contest 2012! Click here to learn more about the STAND AND DELIVER™ program.

Find an Asclera® Provider

Talk to your doctor about Asclera^® for the treatment of uncomplicated spider veins and uncomplicated reticular veins.*

To find an Asclera^® provider near you, please enter your zip code:

*Asclera^® is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera^® has not been studied in varicose veins more than 3 mm in diameter.

About Stand & Deliver

Meet the Finalists

Meet The Advisory Panel

2012 Winner

Contest Terms & Conditions

About Asclera®

IMPORTANT SAFETY INFORMATION FOR PATIENTS:

For intravenous use only.

CONTRAINDICATIONS: Asclera^® (polidocanol) Injection is contraindicated for patients with known allergy (anaphylaxis) to polidocanol and patients with acute vein and blood clotting diseases.

WARNINGS AND PRECAUTIONS:
Anaphylaxis: Severe allergic reactions have been reported following polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are most frequent with use of larger volumes (> 3 mL). The dose of polidocanol should therefore be minimized.Please notify your healthcare provider if you have a known history of severe allergies or allergy to polidocanol.

Accidental injection into an artery can cause severe necrosis, ischemia or gangrene. If this occurs, consult your healthcare provider or a vascular surgeon immediately.

Unintentional injection of Asclera^® outside of the vein can cause pain. If pain is severe, a local anesthetic (without adrenaline) may be injected by your healthcare provider.

Severe adverse local effects, including tissue necrosis, may occur following flow of the product outside of the vein; therefore, the smallest effective volume at each injection site should be used.

After the injection session is completed, apply compression with a stocking or bandage, and walk for 15- 20 minutes. Your healthcare provider will provide monitoring during this period to treat any possible anaphylactic or allergic reactions.

Maintain compression for 2 to 3 days after treatment of spider veins and for 5 to 7 days for reticular veins, or as directed by your Healthcare Provider. For extensive varicosities, longer compression treatment with compression bandages or a gradient compression stocking of a higher compression class is recommended. Post-treatment compression is necessary to reduce the risk of deep vein thrombosis.

ADVERSE REACTIONS: In clinical studies, the following adverse reactions were observed after using Asclera^® and were more common with Asclera^® than placebo: injection site hematoma, injection site irritation, injection site discoloration, injection site pain, injection site itching, injection site warmth, neovascularization, injection site clotting.

You are encouraged to report any suspected adverse events. To report SUSPECTED ADVERSE REACTIONS, contact your Healthcare Provider, Merz Aesthetics at 1-866-862-1211, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

IMPORTANT SAFETY INFORMATION FOR HEALTHCARE PROVIDERS:

For intravenous use only.

CONTRAINDICATIONS: Asclera^® (polidocanol) Injection is contraindicated for patients with known allergy (anaphylaxis) to polidocanol and patients with acute thromboembolic diseases.

WARNINGS AND PRECAUTIONS:
Anaphylaxis: Severe allergic reactions have been reported following polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are most frequent with use of larger volumes (> 3 mL). The dose of polidocanol should therefore be minimized. Be prepared to treat anaphylaxis appropriately.

Accidental Intra-arterial injection can cause severe necrosis, ischemia or gangrene. If this occurs, consult a vascular surgeon immediately.

Inadvertent Perivascular Injection of Asclera^® can cause pain. If pain is severe, a local anesthetic (without adrenaline) may be injected.

Severe adverse local effects, including tissue necrosis, may occur following extravasation; therefore, take care in intravenous needle placement and the smallest effective volume at each injection site should be used.

After the injection session is completed, apply compression with a stocking or bandage, and have the patient walk for 15-20 minutes. Keep the patient under supervision during this period to treat any anaphylactic or allergic reaction.

Maintain compression for 2 to 3 days after treatment of spider veins and for 5 to 7 days for reticular veins. For extensive varicosities, longer compression treatment with compression bandages or a gradient compression stocking of a higher compression class is recommended. Post-treatment compression is necessary to reduce the risk of deep vein thrombosis.

ADVERSE REACTIONS: In clinical studies, the following adverse reactions were observed after using Asclera^® and were more common with Asclera^® than placebo: injection site haematoma, injection site irritation, injection site discoloration, injection site pain, injection site pruritus, injection site warmth, neovascularization, injection site thrombosis.